High serum levels of VEGF-C are indicative of melanoma patients’ responses to immunotherapy, suggesting that elevated VEGF-C levels in circulation may be a biomarker for immunotherapy, despite its association with lymphatic metastasis [90]. Here, VEGFC is linked to melanoma.